Literature DB >> 10882392

Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse.

C Emanueli1, M Bonaria Salis, C Figueroa, J Chao, L Chao, L Gaspa, M C Capogrossi, P Madeddu.   

Abstract

1. In the rat balloon injury model, angiotensin-converting enzyme (ACE) inhibitors prevent vascular remodelling by inhibiting angiotensin II generation and kinin breakdown. We investigated if ACE inhibition also prevents the structural vascular responses to disruption of carotid artery blood flow and if kinin potentiation plays a role in such a protection. 2. Morphometric analysis of the structural alterations caused by ligation of the left carotid artery was performed 14 days after surgery in J129Sv wild-type mice (B(2)(+/+)) drinking normal tap water or water containing captopril (120 mg kg(-1) per day). In addition, the effect of captopril on vascular remodelling was tested in B(2)(+/+) given the bradykinin (BK) B(1) receptor antagonist des-Arg(9)-[Leu(8)]-BK (DALBK, 50 nmol kg(-1) per day, intraperitoneally) or the BK B(2) receptor antagonist D-Arg, [Hyp(3),Thi(5)D-Tic(7),Oic(8)]-BK (icatibant, 1 micromol kg(-1) per day, intraperitoneally), and in B(2) receptor gene knockout mice (B(2)(-/-)). 3. Interruption of blood flow resulted in carotid artery intimal hyperplasia and media thickening in untreated B(2)(+/+), these responses being partially suppressed by captopril. The inhibition of intimal thickening exerted by captopril was reduced in B(2)(+/+) given DALBK or icatibant (P<0.05 for both comparisons) as well as in B(2)(-/-) (P<0.05). Neither antagonism of kinin receptors nor disruption of the B(2) receptor gene altered the suppressive effect of captopril on media thickening. The protection of vascular wall structure was independent of the reduction in blood pressure by captopril. 4. These results demonstrate that kinins participate in the inhibitory effect of captopril on intimal hyperplasia via B(1) and B(2) receptor signalling. Our findings may have important implications in treating vascular remodelling evoked by altered shear stress conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882392      PMCID: PMC1572154          DOI: 10.1038/sj.bjp.0703388

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.

Authors:  K C Wollert; R Studer; K Doerfer; E Schieffer; C Holubarsch; H Just; H Drexler
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

2.  Effects of B1 and B2 kinin receptor antagonists in diabetic mice.

Authors:  A Zuccollo; M Navarro; O Catanzaro
Journal:  Can J Physiol Pharmacol       Date:  1996-05       Impact factor: 2.273

3.  Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts.

Authors:  A Blaukat; S A Alla; M J Lohse; W Müller-Esterl
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

4.  Induction of kinin B1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery.

Authors:  D Pruneau; J M Luccarini; C Robert; P Bélichard
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  A kallikrein-like enzyme in the aorta of normotensive and hypertensive rats.

Authors:  P Madeddu; M V Varoni; M P Demontis; M C Fattaccio; P P Parpaglia; N Glorioso
Journal:  Hypertension       Date:  1994-06       Impact factor: 10.190

6.  Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP.

Authors:  T L Cornwell; E Arnold; N J Boerth; T M Lincoln
Journal:  Am J Physiol       Date:  1994-11

7.  Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells.

Authors:  R Sarkar; E G Meinberg; J C Stanley; D Gordon; R C Webb
Journal:  Circ Res       Date:  1996-02       Impact factor: 17.367

8.  Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart.

Authors:  D Lamontagne; R Nadeau; A Adam
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

9.  Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons.

Authors:  J A Borkowski; R W Ransom; G R Seabrook; M Trumbauer; H Chen; R G Hill; C D Strader; J F Hess
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

Review 10.  Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

Authors:  W Linz; G Wiemer; P Gohlke; T Unger; B A Schölkens
Journal:  Pharmacol Rev       Date:  1995-03       Impact factor: 25.468

View more
  4 in total

1.  Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia.

Authors:  Costanza Emanueli; Maria Bonaria Salis; Tiziana Stacca; Alessandra Pinna; Leonardo Gaspa; Paolo Madeddu; Paolo Maddeddu
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.

Authors:  Jiang Xu; Oscar A Carretero; Edward G Shesely; Nour-Eddine Rhaleb; James J Yang; Michael Bader; Xiao-Ping Yang
Journal:  Exp Physiol       Date:  2008-12-05       Impact factor: 2.969

Review 3.  Recent advances in molecular mechanisms of abdominal aortic aneurysm formation.

Authors:  Suman Annambhotla; Sebastian Bourgeois; Xinwen Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

Review 4.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.